Clene Inc Ordinary Shares CLNN 深 沪
已收盘 09-19 16:00:00 美东时间
6.39
+0.070
+1.11%
华盛通- 最 高6.41
- 今 开6.36
- 成交量 5.38万股
- 最 低 6.1765
- 昨 收 6.32
- 总市值 5739.95万
- 52周最高 7.10
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 2.2801
- 委 比 -22.35%
- 总股本 898.27万
- 历史最高 356.40
- 量 比 0.69
- 振 幅 3.69%
- 历史最低 2.2801
- 每 手 1
- 风险率 1.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Absci(ABSI.US)携手甲骨文(ORCL.US)与AMD(AMD.US)，加速AI驱动的药物研发进程
Absci公司（ABSI.US）于周四宣布，将与甲骨文（ORCL.US）及AMD公司（AMD.US）展开合作，以加快其人工智能（AI）驱动的药物研发工作。
09-12 11:00
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
双奖加冕 | 清源科技荣获“北极星杯”两项重磅大奖
（来源：清源科技Clenergy） 9月9日，光伏行业年度盛会——光伏新时代论坛暨第十四届 “北极星杯” 光伏影响力品牌评选颁奖典礼在江苏南京圆满落幕...
09-10 10:54
Clene Expands Equity Distribution to Raise Capital
Clene ( ($CLNN) ) has issued an announcement. On April 28, 2025, Clene Inc. ent...
09-06 04:49
Clene Inc Announces New Preclinical Data Showing That Its Lead Candidate, CNM-Au8, Improved Cellular Health In A Dopaminergic Neuron Model Of Parkinson's Disease
Novel human preclinical neuronal model for Parkinson's disease demonstrated CNM-Au8's ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression
09-04 20:38
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
Clene Inc. announced new preclinical data showing CNM-Au8 improved mitochondrial health, reduced inflammation, restored cellular metabolism, and normalized gene expression in Parkinson’s disease (PD) dopaminergic neuron models derived from patients. These findings, presented at the Michael J. Fox Foundation H2 Therapeutics Stewardship Meeting, further support CNM-Au8’s potential as a PD treatment. The study also demonstrated CNM-Au8’s favorable s...
09-04 12:30
Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Clene Inc. and its subsidiary Clene Nanomedicine Inc. announced they will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City on September 8-10, 2025, with a virtual presentation available on September 5. Clene focuses on treating neurodegenerative diseases like ALS and MS through its lead candidate CNM-Au8®, targeting mitochondrial function and reducing oxidative stress. Investors can schedule 1x1 meetings vi...
09-02 12:00
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
